Actinium Pharmaceuticals Inc logo

Actinium Pharmaceuticals Inc

AMEX:ATNM (USA)  
$ 7.83 -0.11 (-1.39%) 11:08 PM EST
At Loss
P/B:
4.92
Market Cap:
$ 217.39M
Enterprise V:
$ 136.63M
Volume:
555.97K
Avg Vol (2M):
372.15K
Also Trade In:
Volume:
555.97K
At Loss
Avg Vol (2M):
372.15K

Business Description

Description
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Name Current Vs Industry Vs History
Cash-To-Debt 37.53
Equity-to-Asset 0.49
Debt-to-Equity 0.05
Debt-to-EBITDA -0.04
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 31.7
3-Year EPS without NRI Growth Rate 32.2
3-Year Book Growth Rate 36.1
Name Current Vs Industry Vs History
5-Day RSI 41.76
9-Day RSI 49.85
14-Day RSI 53.08
6-1 Month Momentum % 34.9
12-1 Month Momentum % -8.08

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.87
Quick Ratio 9.87
Cash Ratio 9.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -67.2
Shareholder Yield % -8.86

Financials (Next Earnings Date:2024-05-15 Est.)

ATNM's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with AMEX:ATNM

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Actinium Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1.03
EPS (TTM) ($) -1.93
Beta 0.1
Volatility % 69.73
14-Day RSI 53.08
14-Day ATR ($) 0.670704
20-Day SMA ($) 7.7295
12-1 Month Momentum % -8.08
52-Week Range ($) 4 - 9.8599
Shares Outstanding (Mil) 27.76

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Actinium Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Actinium Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Actinium Pharmaceuticals Inc Frequently Asked Questions

What is Actinium Pharmaceuticals Inc(ATNM)'s stock price today?
The current price of ATNM is $7.83. The 52 week high of ATNM is $9.86 and 52 week low is $4.00.
When is next earnings date of Actinium Pharmaceuticals Inc(ATNM)?
The next earnings date of Actinium Pharmaceuticals Inc(ATNM) is 2024-05-15 Est..
Does Actinium Pharmaceuticals Inc(ATNM) pay dividends? If so, how much?
Actinium Pharmaceuticals Inc(ATNM) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1